Symbols / COGT $35.65 +1.25% Cogent Biosciences, Inc.
COGT Chart
About
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 5.79B |
| Enterprise Value | 5.10B | Income | -328.94M | Sales | — |
| Book/sh | 3.40 | Cash/sh | 5.59 | Dividend Yield | — |
| Payout | 0.00% | Employees | 258 | IPO | — |
| P/E | — | Forward P/E | -51.76 | PEG | — |
| P/S | — | P/B | 10.50 | P/C | — |
| EV/EBITDA | -15.41 | EV/Sales | — | Quick Ratio | 14.09 |
| Current Ratio | 14.23 | Debt/Eq | 37.52 | LT Debt/Eq | — |
| EPS (ttm) | -2.16 | EPS next Y | -0.69 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-05 | ROA | -32.93% |
| ROE | -73.70% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 162.31M |
| Shs Float | 150.97M | Short Float | 10.71% | Short Ratio | 8.43 |
| Short Interest | — | 52W High | 43.73 | 52W Low | 3.72 |
| Beta | 0.47 | Avg Volume | 2.17M | Volume | 417.46K |
| Target Price | $54.17 | Recom | Strong_buy | Prev Close | $35.21 |
| Price | $35.65 | Change | 1.25% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-17 | reit | Wedbush | Outperform → Outperform | $55 |
| 2026-02-18 | main | Piper Sandler | Overweight → Overweight | $52 |
| 2026-01-21 | reit | Wedbush | Outperform → Outperform | $55 |
| 2026-01-06 | main | HC Wainwright & Co. | Buy → Buy | $52 |
| 2025-12-19 | main | JP Morgan | Overweight → Overweight | $67 |
| 2025-12-08 | reit | Needham | Hold → Hold | — |
| 2025-11-13 | main | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-11-11 | main | Baird | Neutral → Neutral | $34 |
| 2025-11-10 | main | Leerink Partners | Outperform → Outperform | $50 |
| 2025-11-04 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2025-10-21 | main | JP Morgan | Overweight → Overweight | $44 |
| 2025-10-16 | init | Stifel | — → Hold | $16 |
| 2025-09-03 | init | Raymond James | — → Strong Buy | $30 |
| 2025-08-25 | main | Guggenheim | Buy → Buy | $20 |
| 2025-08-07 | main | JP Morgan | Overweight → Overweight | $30 |
| 2025-08-06 | main | HC Wainwright & Co. | Buy → Buy | $21 |
| 2025-07-18 | main | Citigroup | Buy → Buy | $22 |
| 2025-07-10 | main | JP Morgan | Overweight → Overweight | $29 |
| 2025-07-08 | main | HC Wainwright & Co. | Buy → Buy | $22 |
| 2025-07-08 | reit | Guggenheim | Buy → Buy | $17 |
- Cogent Biosciences: Blockbuster Potential, Premium Valuation, Still A 'Buy' (NASDAQ:COGT) - Seeking Alpha hu, 02 Apr 2026 17
- [Form 4] Cogent Biosciences, Inc. Insider Trading Activity - Stock Titan Fri, 03 Apr 2026 20
- Is Cogent Biosciences (COGT) One of the Best Multibagger Stocks to Buy According to Billionaires? - Yahoo Finance Sat, 14 Mar 2026 07
- Cogent Biosciences (NASDAQ:COGT) Stock Price Down 10.2% - Should You Sell? - MarketBeat Wed, 01 Apr 2026 17
- A Look At Cogent Biosciences (COGT) Valuation After FDA Acceptance Of Bezuclastinib NDA - Sahm Sun, 05 Apr 2026 19
- (COGT) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com hu, 12 Mar 2026 04
- A Look At Cogent Biosciences (COGT) Valuation After FDA Acceptance Of Bezuclastinib NDA - simplywall.st Sat, 04 Apr 2026 17
- Fairmount funds sells Cogent Biosciences (COGT) shares for $242.6m - Investing.com Wed, 01 Apr 2026 01
- COGT: The Outcome of a Binary PDUFA Rests on FDA’s Verdict in December 2026 - Bitget Sat, 04 Apr 2026 18
- COGT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI Sat, 04 Apr 2026 16
- Cogent files new GIST drug after trial cut progression risk 50% - Stock Titan Wed, 01 Apr 2026 12
- COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know - Yahoo Finance hu, 20 Nov 2025 08
- Technical Reactions to COGT Trends in Macro Strategies - news.stocktradersdaily.com Fri, 03 Apr 2026 06
- Cogent Biosciences (COGT) Is Up 5.5% After FDA NDA Filing For Bezuclastinib In GIST - Has The Bull Case Changed? - Sahm hu, 02 Apr 2026 05
- Fairmount Funds trims Cogent Biosciences (COGT) position after 7M-share block sale - Stock Titan Wed, 01 Apr 2026 01
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
333.36
+20.81%
|
275.94
+32.58%
|
208.13
+40.78%
|
147.84
|
| Research And Development |
|
269.78
+15.96%
|
232.66
+33.90%
|
173.75
+42.86%
|
121.63
|
| Selling General And Administration |
|
63.58
+46.91%
|
43.28
+25.91%
|
34.38
+31.14%
|
26.21
|
| General And Administrative Expense |
|
63.58
+46.91%
|
43.28
+25.91%
|
34.38
+31.14%
|
26.21
|
| Other Gand A |
|
63.58
+46.91%
|
43.28
+25.91%
|
34.38
+31.14%
|
26.21
|
| Total Expenses |
|
333.36
+20.81%
|
275.94
+32.58%
|
208.13
+40.78%
|
147.84
|
| Operating Income |
|
-333.36
-20.81%
|
-275.94
-32.58%
|
-208.13
-40.78%
|
-147.84
|
| Total Operating Income As Reported |
|
-333.36
-20.81%
|
-275.94
-32.58%
|
-208.13
-40.78%
|
-147.84
|
| EBITDA |
|
-321.29
-27.75%
|
-251.51
-33.20%
|
-188.82
-33.01%
|
-141.96
|
| Normalized EBITDA |
|
-314.11
-24.89%
|
-251.51
-33.20%
|
-188.82
-33.01%
|
-141.96
|
| Reconciled Depreciation |
|
4.58
+5.33%
|
4.35
+21.27%
|
3.59
-38.96%
|
5.88
|
| EBIT |
|
-325.88
-27.37%
|
-255.86
-32.98%
|
-192.41
-30.15%
|
-147.84
|
| Total Unusual Items |
|
-7.18
|
0.00
|
0.00
|
—
|
| Total Unusual Items Excluding Goodwill |
|
-7.18
|
0.00
|
0.00
|
—
|
| Special Income Charges |
|
-7.18
|
0.00
|
0.00
|
—
|
| Other Special Charges |
|
7.18
|
—
|
—
|
—
|
| Net Income |
|
-328.94
-28.56%
|
-255.86
-32.98%
|
-192.41
-37.20%
|
-140.24
|
| Pretax Income |
|
-328.94
-28.56%
|
-255.86
-32.98%
|
-192.41
-37.20%
|
-140.24
|
| Net Non Operating Interest Income Expense |
|
11.63
-35.72%
|
18.09
+38.32%
|
13.08
+227.83%
|
3.99
|
| Interest Expense Non Operating |
|
3.06
|
0.00
|
0.00
|
—
|
| Net Interest Income |
|
11.63
-35.72%
|
18.09
+38.32%
|
13.08
+227.83%
|
3.99
|
| Interest Expense |
|
3.06
|
0.00
|
0.00
|
—
|
| Interest Income Non Operating |
|
14.69
-18.79%
|
18.09
+38.32%
|
13.08
+227.83%
|
3.99
|
| Interest Income |
|
14.69
-18.79%
|
18.09
+38.32%
|
13.08
+227.83%
|
3.99
|
| Other Income Expense |
|
-7.20
-461.50%
|
1.99
-24.63%
|
2.64
-26.77%
|
3.61
|
| Other Non Operating Income Expenses |
|
-0.02
-101.00%
|
1.99
-24.63%
|
2.64
-26.77%
|
3.61
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-328.94
-28.56%
|
-255.86
-32.98%
|
-192.41
-37.20%
|
-140.24
|
| Net Income From Continuing Operation Net Minority Interest |
|
-328.94
-28.56%
|
-255.86
-32.98%
|
-192.41
-37.20%
|
-140.24
|
| Net Income From Continuing And Discontinued Operation |
|
-328.94
-28.56%
|
-255.86
-32.98%
|
-192.41
-37.20%
|
-140.24
|
| Net Income Continuous Operations |
|
-328.94
-28.56%
|
-255.86
-32.98%
|
-192.41
-37.20%
|
-140.24
|
| Normalized Income |
|
-321.76
-25.76%
|
-255.86
-32.98%
|
-192.41
-37.20%
|
-140.24
|
| Net Income Common Stockholders |
|
-328.94
-28.56%
|
-255.86
-32.98%
|
-192.41
-37.20%
|
-140.24
|
| Diluted EPS |
|
—
|
-2.32
+4.29%
|
-2.42
-1.26%
|
-2.39
|
| Basic EPS |
|
—
|
-2.32
+4.29%
|
-2.42
-1.26%
|
-2.39
|
| Basic Average Shares |
|
—
|
110.46
+38.67%
|
79.66
+35.61%
|
58.74
|
| Diluted Average Shares |
|
—
|
110.46
+38.67%
|
79.66
+35.61%
|
58.74
|
| Diluted NI Availto Com Stockholders |
|
-328.94
-28.56%
|
-255.86
-32.98%
|
-192.41
-37.20%
|
-140.24
|
| Gain On Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
937.61
+185.94%
|
327.90
+4.61%
|
313.44
+4.20%
|
300.81
|
| Current Assets |
|
910.36
+207.06%
|
296.47
+9.49%
|
270.77
+2.19%
|
264.97
|
| Cash Cash Equivalents And Short Term Investments |
|
900.76
+213.77%
|
287.08
+8.04%
|
265.71
+2.48%
|
259.28
|
| Cash And Cash Equivalents |
|
312.01
+217.84%
|
98.17
+84.42%
|
53.23
-61.95%
|
139.89
|
| Other Short Term Investments |
|
588.75
+211.65%
|
188.91
-11.09%
|
212.48
+77.97%
|
119.39
|
| Prepaid Assets |
|
—
|
—
|
—
|
4.43
|
| Restricted Cash |
|
—
|
—
|
0.00
-100.00%
|
1.25
|
| Other Current Assets |
|
9.59
+2.08%
|
9.39
+85.64%
|
5.06
+14.11%
|
4.43
|
| Total Non Current Assets |
|
27.25
-13.28%
|
31.43
-26.34%
|
42.67
+19.03%
|
35.84
|
| Net PPE |
|
23.54
-11.40%
|
26.56
-12.45%
|
30.34
-2.43%
|
31.10
|
| Gross PPE |
|
32.21
-1.42%
|
32.68
-3.91%
|
34.01
+4.64%
|
32.50
|
| Accumulated Depreciation |
|
-8.68
-41.93%
|
-6.12
-66.85%
|
-3.67
-161.60%
|
-1.40
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
18.08
-10.05%
|
20.10
-8.64%
|
22.00
-5.65%
|
23.32
|
| Machinery Furniture Equipment |
|
2.06
+3.41%
|
2.00
+4.50%
|
1.91
+34.53%
|
1.42
|
| Construction In Progress |
|
0.76
+1760.98%
|
0.04
+51.85%
|
0.03
-94.40%
|
0.48
|
| Other Properties |
|
8.85
+9.45%
|
8.08
+5.87%
|
7.63
+38.64%
|
5.51
|
| Leases |
|
2.46
+0.00%
|
2.46
+1.03%
|
2.44
+37.27%
|
1.78
|
| Investments And Advances |
|
—
|
0.00
-100.00%
|
7.46
|
0.00
|
| Other Non Current Assets |
|
3.72
-23.55%
|
4.86
-0.04%
|
4.86
+2.51%
|
4.75
|
| Total Liabilities Net Minority Interest |
|
301.24
+320.65%
|
71.61
+28.72%
|
55.63
+23.43%
|
45.08
|
| Current Liabilities |
|
63.95
+14.80%
|
55.71
+45.96%
|
38.17
+42.16%
|
26.85
|
| Payables And Accrued Expenses |
|
39.92
-3.83%
|
41.51
+56.85%
|
26.47
+53.35%
|
17.26
|
| Payables |
|
9.50
-20.89%
|
12.01
+12.75%
|
10.65
+82.39%
|
5.84
|
| Accounts Payable |
|
9.50
-20.89%
|
12.01
+12.75%
|
10.65
+82.39%
|
5.84
|
| Current Accrued Expenses |
|
30.42
+3.11%
|
29.50
+86.57%
|
15.81
+38.50%
|
11.42
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
15.74
+28.40%
|
12.26
+24.15%
|
9.87
+62.86%
|
6.06
|
| Current Debt And Capital Lease Obligation |
|
1.55
-1.15%
|
1.56
+12.91%
|
1.39
-2.60%
|
1.42
|
| Current Capital Lease Obligation |
|
1.55
-1.15%
|
1.56
+12.91%
|
1.39
-2.60%
|
1.42
|
| Current Deferred Liabilities |
|
—
|
—
|
—
|
1.70
|
| Current Deferred Revenue |
|
—
|
—
|
—
|
1.70
|
| Other Current Liabilities |
|
6.75
+1708.31%
|
0.37
-15.42%
|
0.44
-79.04%
|
2.10
|
| Total Non Current Liabilities Net Minority Interest |
|
237.28
+1392.16%
|
15.90
-8.96%
|
17.47
-4.16%
|
18.23
|
| Long Term Debt And Capital Lease Obligation |
|
237.25
+1391.95%
|
15.90
-8.96%
|
17.47
-4.16%
|
18.23
|
| Long Term Debt |
|
222.90
|
—
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
14.36
-9.73%
|
15.90
-8.96%
|
17.47
-4.16%
|
18.23
|
| Other Non Current Liabilities |
|
0.03
|
—
|
—
|
—
|
| Stockholders Equity |
|
636.37
+148.31%
|
256.29
-0.59%
|
257.80
+0.81%
|
255.74
|
| Common Stock Equity |
|
546.98
+275.45%
|
145.69
-26.33%
|
197.77
+4.14%
|
189.91
|
| Capital Stock |
|
89.55
-19.11%
|
110.71
+84.15%
|
60.12
-8.77%
|
65.90
|
| Common Stock |
|
0.16
+46.36%
|
0.11
+27.91%
|
0.09
+22.86%
|
0.07
|
| Preferred Stock |
|
89.39
-19.17%
|
110.60
+84.23%
|
60.03
-8.80%
|
65.83
|
| Share Issued |
|
160.98
+45.73%
|
110.46
+28.26%
|
86.12
+23.22%
|
69.89
|
| Ordinary Shares Number |
|
160.98
+45.73%
|
110.46
+28.26%
|
86.12
+23.22%
|
69.89
|
| Additional Paid In Capital |
|
1,734.88
+72.69%
|
1,004.61
+25.41%
|
801.06
+33.25%
|
601.15
|
| Retained Earnings |
|
-1,188.42
-38.27%
|
-859.48
-42.39%
|
-603.62
-46.79%
|
-411.21
|
| Gains Losses Not Affecting Retained Earnings |
|
0.35
-20.58%
|
0.45
+81.71%
|
0.25
+336.54%
|
-0.10
|
| Other Equity Adjustments |
|
0.35
-20.58%
|
0.45
+81.71%
|
0.25
+336.54%
|
-0.10
|
| Total Equity Gross Minority Interest |
|
636.37
+148.31%
|
256.29
-0.59%
|
257.80
+0.81%
|
255.74
|
| Total Capitalization |
|
859.27
+235.28%
|
256.29
-0.59%
|
257.80
+0.81%
|
255.74
|
| Working Capital |
|
846.40
+251.55%
|
240.76
+3.51%
|
232.60
-2.32%
|
238.12
|
| Invested Capital |
|
769.87
+428.45%
|
145.69
-26.33%
|
197.77
+4.14%
|
189.91
|
| Total Debt |
|
238.80
+1267.13%
|
17.47
-7.35%
|
18.85
-4.05%
|
19.65
|
| Capital Lease Obligations |
|
15.90
-8.96%
|
17.47
-7.35%
|
18.85
-4.05%
|
19.65
|
| Net Tangible Assets |
|
636.37
+148.31%
|
256.29
-0.59%
|
257.80
+0.81%
|
255.74
|
| Tangible Book Value |
|
546.98
+275.45%
|
145.69
-26.33%
|
197.77
+4.14%
|
189.91
|
| Available For Sale Securities |
|
—
|
—
|
7.46
|
—
|
| Investmentin Financial Assets |
|
—
|
0.00
-100.00%
|
7.46
|
0.00
|
| Preferred Stock Equity |
|
89.39
-19.17%
|
110.60
+84.23%
|
60.03
-8.80%
|
65.83
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-264.44
-27.26%
|
-207.79
-35.26%
|
-153.62
-29.49%
|
-118.64
|
| Cash Flow From Continuing Operating Activities |
|
-264.44
-27.26%
|
-207.79
-35.26%
|
-153.62
-29.49%
|
-118.64
|
| Net Income From Continuing Operations |
|
-328.94
-28.56%
|
-255.86
-32.98%
|
-192.41
-37.20%
|
-140.24
|
| Depreciation Amortization Depletion |
|
4.58
+5.33%
|
4.35
+21.27%
|
3.59
-38.96%
|
5.88
|
| Depreciation |
|
4.58
+5.33%
|
4.35
+21.27%
|
3.59
-38.96%
|
5.88
|
| Depreciation And Amortization |
|
4.58
+5.33%
|
4.35
+21.27%
|
3.59
-38.96%
|
5.88
|
| Other Non Cash Items |
|
0.60
|
—
|
-1.70
-25.00%
|
-1.36
|
| Stock Based Compensation |
|
46.08
+15.95%
|
39.74
+29.78%
|
30.62
+66.71%
|
18.37
|
| Asset Impairment Charge |
|
—
|
0.00
|
0.00
+100.00%
|
-0.40
|
| Operating Gains Losses |
|
7.18
|
—
|
0.01
|
—
|
| Gain Loss On Sale Of PPE |
|
0.00
|
0.00
-100.00%
|
0.01
|
0.00
|
| Change In Working Capital |
|
8.01
-30.92%
|
11.60
+1.35%
|
11.44
+1423.57%
|
0.75
|
| Change In Receivables |
|
—
|
—
|
—
|
—
|
| Changes In Account Receivables |
|
—
|
—
|
—
|
—
|
| Change In Prepaid Assets |
|
-0.20
+95.50%
|
-4.33
-592.33%
|
-0.63
+57.87%
|
-1.49
|
| Change In Payables And Accrued Expense |
|
8.18
-52.77%
|
17.31
+33.36%
|
12.98
+8.69%
|
11.95
|
| Change In Accrued Expense |
|
10.69
-33.03%
|
15.96
+95.30%
|
8.17
-14.77%
|
9.59
|
| Change In Payable |
|
-2.51
-284.76%
|
1.36
-71.78%
|
4.81
+104.03%
|
2.36
|
| Change In Account Payable |
|
-2.51
-284.76%
|
1.36
-71.78%
|
4.81
+104.03%
|
2.36
|
| Change In Other Current Assets |
|
1.56
+77950.00%
|
0.00
+101.68%
|
-0.12
+88.31%
|
-1.02
|
| Change In Other Current Liabilities |
|
-1.53
-10.53%
|
-1.39
-74.12%
|
-0.80
+90.84%
|
-8.69
|
| Investing Cash Flow |
|
-399.53
-1143.80%
|
38.28
+139.13%
|
-97.82
+21.56%
|
-124.72
|
| Cash Flow From Continuing Investing Activities |
|
-399.53
-1143.80%
|
38.28
+139.13%
|
-97.82
+21.56%
|
-124.72
|
| Net PPE Purchase And Sale |
|
-1.55
-171.20%
|
-0.57
+79.51%
|
-2.80
+59.26%
|
-6.86
|
| Purchase Of PPE |
|
-1.55
-171.20%
|
-0.57
+79.51%
|
-2.80
+59.26%
|
-6.86
|
| Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Capital Expenditure |
|
-1.55
-171.20%
|
-0.57
+79.51%
|
-2.80
+59.26%
|
-6.86
|
| Net Investment Purchase And Sale |
|
-397.97
-1124.41%
|
38.85
+140.88%
|
-95.03
+19.37%
|
-117.86
|
| Purchase Of Investment |
|
-687.17
-168.84%
|
-255.60
+26.72%
|
-348.80
-96.12%
|
-177.85
|
| Sale Of Investment |
|
289.20
-1.78%
|
294.45
+16.03%
|
253.78
+322.96%
|
60.00
|
| Financing Cash Flow |
|
878.23
+309.53%
|
214.45
+31.13%
|
163.54
-0.01%
|
163.56
|
| Cash Flow From Continuing Financing Activities |
|
878.23
+309.53%
|
214.45
+31.13%
|
163.54
-0.01%
|
163.56
|
| Net Issuance Payments Of Debt |
|
217.76
|
0.00
|
0.00
|
—
|
| Issuance Of Debt |
|
272.39
|
0.00
|
0.00
|
—
|
| Repayment Of Debt |
|
-54.63
|
0.00
|
0.00
|
—
|
| Long Term Debt Issuance |
|
49.29
|
0.00
|
0.00
|
—
|
| Long Term Debt Payments |
|
-54.63
|
0.00
|
0.00
|
—
|
| Net Long Term Debt Issuance |
|
-5.34
|
0.00
|
0.00
|
—
|
| Short Term Debt Issuance |
|
223.10
|
0.00
|
0.00
|
—
|
| Net Short Term Debt Issuance |
|
223.10
|
0.00
|
0.00
|
—
|
| Net Common Stock Issuance |
|
159.32
-25.32%
|
213.34
+31.84%
|
161.82
-0.08%
|
161.94
|
| Proceeds From Stock Option Exercised |
|
552.67
+49467.00%
|
1.11
-35.06%
|
1.72
+6.45%
|
1.61
|
| Net Other Financing Charges |
|
-51.52
|
—
|
—
|
—
|
| Changes In Cash |
|
214.26
+376.82%
|
44.94
+151.11%
|
-87.91
-10.17%
|
-79.80
|
| Beginning Cash Position |
|
98.17
+84.42%
|
53.23
-62.29%
|
141.14
-36.12%
|
220.94
|
| End Cash Position |
|
312.43
+218.27%
|
98.17
+84.42%
|
53.23
-62.29%
|
141.14
|
| Free Cash Flow |
|
-266.00
-27.66%
|
-208.36
-33.21%
|
-156.42
-24.64%
|
-125.50
|
| Interest Paid Supplemental Data |
|
2.02
|
0.00
|
—
|
—
|
| Amortization Of Securities |
|
-1.96
+74.25%
|
-7.62
-47.28%
|
-5.17
-215.81%
|
-1.64
|
| Common Stock Issuance |
|
159.32
-25.32%
|
213.34
+31.84%
|
161.82
-0.08%
|
161.94
|
| Issuance Of Capital Stock |
|
159.32
-25.32%
|
213.34
+31.84%
|
161.82
-0.08%
|
161.94
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-03 View
- 42026-03-31 View
- 10-K2026-02-17 View
- 8-K2026-02-17 View
- 42026-01-22 View
- 42026-01-05 View
- 42025-12-30 View
- 42025-12-30 View
- 42025-12-30 View
- 42025-12-30 View
- 42025-12-19 View
- 42025-12-19 View
- 42025-12-19 View
- 42025-12-19 View
- 42025-12-19 View
- 42025-12-19 View
- 8-K2025-12-08 View
- 8-K2025-11-18 View
- 8-K2025-11-13 View
- 8-K2025-11-10 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|